<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709889</url>
  </required_header>
  <id_info>
    <org_study_id>SCRX001-006</org_study_id>
    <nct_id>NCT02709889</nct_id>
  </id_info>
  <brief_title>Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemcentrx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stemcentrx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific
      delta-like protein 3-expressing advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label study involving multiple specific advanced solid tumor
      types, consisting of a dose escalation Part A followed by an expansion Part B. Cancer
      subtypes will be studied in separate disease-specific cohorts in both Parts. Eight separate
      cohorts will enroll malignant melanoma, medullary thyroid cancer (MTC), glioblastoma, large
      cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC), high-grade
      gastroenteropancreatic (GEP), neuroendocrine carcinoma (NEC), other NEC, and solid tumors
      other than the above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Baseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Cycles 1, 2 and 4: day 1 (pre-dose, 30 min post-dose, 6 hours post-dose), 3, 8, 15, 29; Cycles 3, 5 and above: day 1, 8, 15, 29; up to 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Cycles 1, 2 and 4: day 1 (pre-dose, 30 min post-dose, 6 hours post-dose), 3, 8, 15, 29; Cycles 3, 5 and above: day 1, 8, 15, 29; up to 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-therapeutic Antibodies (ATA)</measure>
    <time_frame>Cycles 1, 2 and 4: day 1 (pre-dose, 30 min post-dose, 6 hours post-dose), 3, 8, 15, 29; Cycles 3, 5 and above: day 1, 8, 15, 29; up to 1 year.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">378</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>Glioblastoma</condition>
  <condition>Large Cell Neuroendocrine Carcinoma</condition>
  <condition>Neuroendocrine Prostate Cancer</condition>
  <condition>High Grade Gastroenteropancreatic Neuroendocrine Carcinoma</condition>
  <condition>Other Neuroendocrine Carcinoma</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Rovalpituzumab tesirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rovalpituzumab tesirine 0.2-0.4 mg/kg will be administered intravenously on Day 1 of each 6-week cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rovalpituzumab tesirine</intervention_name>
    <arm_group_label>Rovalpituzumab tesirine</arm_group_label>
    <other_name>SC16LD6.5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, unresectable advanced solid malignancy with documented
             disease progression after at least 1 prior systemic therapy

          -  Measurable disease as defined by RECIST 1.1

          -  DLL3-expressing malignancy based on central immunohistochemical (IHC) testing of
             representative baseline tumor tissue (archived tissue or on-study biopsy). Positive is
             defined as staining in ≥ 1% of tumor cells.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Minimum life expectancy of at least 12 weeks

          -  Subjects with a history of central nervous system (CNS) metastases must have
             documentation of stable or improved brain imaging for at least 2 weeks after
             completion of definitive treatment and within 2 weeks prior to first dose of Study
             Drug, off or on a stable dose of corticosteroids. Definitive treatment may include
             surgical resection, whole brain irradiation, and/or stereotactic radiation therapy.
             (Applicable to tumor types of non-CNS primary origin only)

          -  Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior
             to initiation of study drug administration

          -  Adequate hematologic and organ function as confirmed by laboratory values

          -  Last dose of any prior therapy administered by the following time intervals before the
             first dose of study drug:

               1. Chemotherapy, small molecule inhibitors, radiation, and/or other investigational
                  anticancer agents (excluding investigational monoclonal antibodies): 2 weeks.

               2. Immune-checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4),
                  monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell
                  or other cell-based therapies: 4 weeks (2 weeks with documented disease
                  progression).

          -  Females of childbearing potential must have a negative beta human chorionic
             gonadotropin (β-hCG) pregnancy test result within 7 days prior to the first dose of
             study drug. Females of non-childbearing potential are those who are postmenopausal
             greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.

        Exclusion Criteria:

          -  Any significant medical condition, including any suggested by screening laboratory
             findings that, in the opinion of the investigator or sponsor, may place the subject at
             undue risk from the study, including but not necessarily limited to uncontrolled
             hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic
             obstructive pulmonary disease requiring hospitalization within 3 months) or
             neurological disorder (e.g., seizure disorder active within 3 months).

          -  Documented history of a cerebral vascular event (stroke or transient ischemic attack),
             unstable angina, myocardial infarction, or cardiac symptoms consistent with New York
             Heart Association (NYHA) Class III-IV (see Appendix 12.4) within 6 months prior to
             their first dose of study drug.

          -  Recent or ongoing serious infection, including:

               1. Any active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or
                  fungal infection within 2 weeks of the first dose of the study drug. Routine
                  antimicrobial prophylaxis is permitted.

               2. Known seropositivity for or active infection by human immunodeficiency virus
                  (HIV).

               3. Active Hepatitis B (by surface antigen expression or polymerase chain reaction)
                  or C (by polymerase chain reaction) infection or on hepatitis-related antiviral
                  therapy within 6 months of first dose of study drug.

          -  Women who are pregnant or breastfeeding

          -  Systemic therapy with corticosteroids at &gt;20 mg/day prednisone or equivalent within 1
             week prior to the first dose of study drug

          -  History of another invasive malignancy that has not been in remission for at least 3
             years. Exceptions to the 3year limit include non-melanoma skin cancer, curatively
             treated localized prostate cancer, ductal carcinoma in situ, and cervical cancer in
             situ on biopsy or squamous intraepithelial lesion on PAP smear.

          -  Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, prior participation in a
             rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab
             tesirine or excipient contained in the drug formulation, unless undergoing retreatment
             with rovalpituzumab tesirine in the context of this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Luo, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Stemcentrx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SCRX001-006 Study Team</last_name>
    <email>STEM_scrx001-006@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-256-6444</phone>
    </contact>
    <investigator>
      <last_name>Jiaxin Niu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Alan Bryce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-423-2133</phone>
    </contact>
    <investigator>
      <last_name>Andrew Hendifar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-794-7700</phone>
    </contact>
    <investigator>
      <last_name>Allan Pantuck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-827-3222</phone>
      <email>communications@cc.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>720-848-0637</phone>
    </contact>
    <investigator>
      <last_name>Karl Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>720-754-2610</phone>
    </contact>
    <investigator>
      <last_name>Gerald Falchook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-273-8675</phone>
    </contact>
    <investigator>
      <last_name>Frederic J Kaye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>888-663-3488</phone>
    </contact>
    <investigator>
      <last_name>Heloisa Soares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Taofeek Owonikoko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>866-340-4488</phone>
    </contact>
    <investigator>
      <last_name>Anthony Lowell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-464-6713</phone>
    </contact>
    <investigator>
      <last_name>Christine Hann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-420-3951</phone>
    </contact>
    <investigator>
      <last_name>Anna Farago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-284-2511</phone>
    </contact>
    <investigator>
      <last_name>Aaron Mansfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-362-1000</phone>
    </contact>
    <investigator>
      <last_name>Saiama Waqar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>732-235-8675</phone>
    </contact>
    <investigator>
      <last_name>Jyoti Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-275-7724</phone>
    </contact>
    <investigator>
      <last_name>Grace K Dy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-962-8215</phone>
    </contact>
    <investigator>
      <last_name>Himisha Beltran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-684-6342</phone>
    </contact>
    <investigator>
      <last_name>Tian Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-494-1080</phone>
    </contact>
    <investigator>
      <last_name>Matthew Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>864-455-7070</phone>
    </contact>
    <investigator>
      <last_name>Ki Young Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-566-3000</phone>
    </contact>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>817-850-2230</phone>
    </contact>
    <investigator>
      <last_name>Stephen Richey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-590-5652</phone>
      <phone_ext>1</phone_ext>
    </contact>
    <investigator>
      <last_name>David S. Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>888-424-2100</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Whisenant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>703-280-5390</phone>
    </contact>
    <investigator>
      <last_name>Alexander I Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Oncology</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>360-944-9889</phone>
    </contact>
    <investigator>
      <last_name>David Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

